|
|
|
|
|
|
|
|
|
20.07.26 - 15:21
|
Tempus AI will AKTIONÄR-Tipp schlucken – 70 Prozent seit Ende Mai (Der Aktionaer)
|
|
|
Es gab bereits Gerüchte, doch nun ist es amtlich: Für die Aktionäre des Krebsgenomik-Spezialisten Personalis hat Tempus AI ein Übernahmeangebot vorgelegt. AKTIONÄR-Leser können sich auf ein ordentliches Kursplus seit der Empfehlung Ende Mai freuen. Die Aktie von Tempus AI hingegen wird in einer ersten Reaktion abgestraft und fällt zeitweise gut sieben Prozent....
|
|
|
20.07.26 - 14:39
|
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (Business Wire)
|
|
|
Acquisition brings together Personalis' MRD technology with Tempus' commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth
Expands Tempus' reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunityFREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has entered into a definitive agreement to be acquired by Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care. The acquisition will expand Tempus capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.
Under the terms of the agreement, Personalis shareholders will receive consideration of $16.25 per share of common stock, represent...
|
|
|
20.07.26 - 14:33
|
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform (Business Wire)
|
|
|
Acquisition brings together Personalis' MRD technology with Tempus' commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth
Expands Tempus' reach across the cancer care continuum and accelerates access to industry-leading technology within the rapidly emerging MRD market, a $20 billion opportunityCHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diagnosis and treatment selection, to recurrence and monitoring.
Under the terms of the agreement, Personalis shareholders will receive consideration of $16.25 per share of common stock, representing a total enterprise value of $1.5 billion, net of Tempus' exist...
|
|
|
|
|
09.07.26 - 15:03
|
Tempus to Report Second Quarter 2026 Financial Results on July 30 (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026.
The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers.
The live audio webcast will be accessible through the “Events” section of the Tempus Investor Relations website or by clicking here. Alternatively, the call can be accessed via the following:
Conference ID: 9053038
United States - New York: (646) 307-1963
USA & Canada - Toll-Free: (800) 715-9871
For those unable to listen to the live broadcast, a recording will be available on the website following the call.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.06.26 - 14:33
|
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH (Business Wire)
|
|
|
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH, a next-generation sequencing (NGS) test that uses a whole-genome sequencing (WGS) approach for the detection of actionable oncologic targets in peripheral blood and bone marrow samples from patients with hematologic malignancies.
Tempus first announced the xH assay for research use only in January 2025. The test was developed for use in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and overlap syndromes (MDS/MPN). It is optimized for myeloid neoplasms and is designed to support disease understanding, biomarker discovery, and therapeutic research.
The performance of the Tempus xH assay was established in an analytical validation study using 235 unique specimens, including whole blood, bone marrow, and cell lines. Assay performance was evaluated by comparison with ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
